Single technology appraisal (STA)

Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (review of TA196) [ID696]

Comments from Novartis on the Appraisal Consultation Document

Novartis are pleased that the Committee have given a positive preliminary recommendation to approve imatinib as an adjuvant treatment for gastro-intestinal stromal tumours in patients at high-risk of disease recurrence. The ACD provides both a balanced assessment of the evidence submitted, and an accurate representation of the discussions from the first Appraisal Committee meeting.